Navigation Links
Improvements needed in genomic test result discussions
Date:3/8/2010

A new study has found that one in three early-stage breast cancer patients who received genomic testing when deciding about treatment options felt they did not fully understand their discussions with physicians about their test results and their risk of recurrence. About one in four experienced distress when receiving their test results.

Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest there is room for improvement in communicating cancer recurrence risks and treatment decisions with patients.

Genomic testing is an increasingly important part of care for patients after they are diagnosed with early stage breast cancer. The test, which looks at 21 genes in breast tumors removed during surgery, can indicate the chance the patient's cancer will recur. Such information can help guide decisions by physicians and patients about chemotherapy treatments. Patients with a high risk of recurrence may opt for more aggressive treatment, while those with lower risk may safely avoid over-treatment and its potential side effects. It can be challenging, however, for physicians to determine the best way to talk to patients about their test results and to use the results to make important treatment decisions with patients. Currently, there is little consensus regarding the most effective method to communicate risk information to patients.

Noel Brewer, PhD, assistant professor of health behavior and health education at University of North Carolina's Gillings School of Global Public Health, and Janice Tzeng, MPH, who worked on this study as a graduate student at the school, led a team that examined how women with breast cancer received and understood cancer recurrence risk information after receiving a genomic diagnostic test called Oncotype DX, that is gaining widespread acceptance by oncologists and insurers.

To find out more about women's reactions, investigators mailed surveys to 77 women with early-stage, estrogen receptor-positive breast cancer who received Oncotype DX between 2004 and 2009. The study was funded by a five-year grant from the American Cancer Society.

"Almost all women agreed that having the test gave them a better understanding of their treatment options' chances of success," said Brewer. "Most women said that they would have the test if they had to decide again today, and that they would recommend the test to other women in their same situation," he added. Also, most women accurately recalled their genomic-based recurrence risk results, he said. These findings suggest that patients have a positive attitude about genomic testing, and testing helps them better understand their treatment options.

While many women understood discussions about their genomic test results, a third reported not fully understanding these discussions. Although 87 percent of women received a low or intermediate breast cancer recurrence risk score, about a quarter of the women experienced distress when receiving their test results. The authors concluded that their findings suggest a need to improve risk communication and treatment decision making after patients undergo genomic testing.


'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Related medicine news :

1. Innovation Initiative Underway for Health Records Improvements
2. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
3. Banner Health Systems Adopts Quantros Regulatory Reporting Management (RRM) to Manage Clinical Quality and Performance Data and Support Improvements in Quality of Care
4. TAXUS(R) Liberte(R) Stent Continues to Demonstrate Significant Improvements Over TAXUS(R) Express(R) Stent in Small Vessels and Long Lesions
5. Heavy-drinking colleges showing no improvements
6. National Changing Diabetes Program Supports Improvements in Health Cost Estimates
7. Steady Improvements Seen for Young Blood Cancer Patients
8. AbbeyMoor Medical Receives FDA Approval for Design Improvements to The Spanner(TM) Prostatic Stent
9. Ceremony at Passavant Area Hospital to Launch Efficiency Improvements
10. Use of Mealtime Pramlintide Added to Basal Insulin Showed Similar Improvements in Glycemic Control Compared to Rapid-Acting Insulin, With Lower Risk of Hypoglycemia and Without Weight Gain: Data Presented at ADA 2009
11. Compressus Delivers Imaging Productivity & Efficiency Improvements in Next Generation MEDxConnect(TM) Workflow Management Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... Visalia, CA (PRWEB) , ... July 20, 2017 , ... ... has announced the addition of Horine Chiropractic , directed by Dr. Russell Horine, ... as it is completely family run with Dr. Russell Horine serving as the clinic ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Dermatology Clinic announced today ... received his BS in Biology from LSU, graduating summa cum laude. He attended Emory ... After his residency in St. Louis, Dr. Dunbar moved to New York to complete ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... services since 2014, top travel insurance solution company VisitorsCoverage Inc. has launched TMQuotes, ... all major international travel insurance products online, under their own brand. The online ...
(Date:7/20/2017)... ... ... Dr. Jig Patel is pleased to announce openings for new patients who are ... difficulties that face people who are missing teeth , he offers education about ... and bridges. Not only does an implant improve oral health, it also restores the ...
(Date:7/20/2017)... ... July 19, 2017 , ... ... hiring senior healthcare project manager, Josh Christensen. As a leader in healthcare construction, ... to further its healthcare resume in the Midwest with Josh now on board. ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... MINNEAPOLIS , July 5, 2017 Pace Analytical, a company of ... announcing today that they have acquired ESC Lab Sciences, further solidifying their position ... the United States . ... Steve Vanderboom- President and CEO of Pace Analytical ... of ESC Lab Sciences out of Mt Juliet, TN , ...
(Date:7/1/2017)... 30, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... conference call will be broadcast live over the Internet on ... news release detailing the quarterly results will be made available ... call. The live audio webcast can be accessed ... It will be archived for replay following the conference call. ...
(Date:6/30/2017)... Medical (AVACEN) announced the publication of new research in the peer-reviewed ... AVACEN Treatment Method to significantly reduce the widespread pain ... ... ... 200 to 400 million people worldwide according to The National Fibromyalgia ...
Breaking Medicine Technology: